Chemically activatable viral capsid functionalized for cancer targeting

Chun Chieh Chen, Li Xing, Marie Stark, Tingwei Ou, Prasida Holla, Kai Xiao, Shizuo G. Kamita, Bruce D. Hammock, Kit Lam, R. Holland Cheng

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aim: To design a theranostic capsule using the virus-like nanoparticle of the hepatitis E virus modified to display breast cancer cell targeting functional group (LXY30). Methods: Five surface-exposed residues were mutated to cysteine to allow conjugation to maleimide-linked chemical groups via thiol-selective linkages. Engineered virus-like nanoparticles were then covalently conjugated to a breast cancer recognized ligand, LXY30 and an amine-coupled near-infrared fluorescence dye. Results: LXY30-HEV VLP was checked for its binding and entry to a breast cancer cell line and for tumor targeting in vivo to breast cancer tissue in mice. The engineered virus-like nanoparticle not only targeted cancer cells, but also appeared immune silent to native hepatitis E virus antibodies due to epitope disruption at the antibody-binding site. Conclusion: These results demonstrate the production of a theranostic capsule suitable for cancer diagnostics and therapeutics based on surface modification of a highly stable virus-like nanoparticle.

Original languageEnglish (US)
Pages (from-to)377-390
Number of pages14
JournalNanomedicine
Volume11
Issue number4
DOIs
StatePublished - Feb 1 2016

Fingerprint

Capsid
Viruses
Nanoparticles
targeting
cancer
virus
Breast Neoplasms
Hepatitis E virus
Capsules
Neoplasms
hepatitis
Cells
Antibody Binding Sites
Antibodies
antibody
contagious disease
Tumor Cell Line
Sulfhydryl Compounds
Amines
Cysteine

Keywords

  • cycloaddition of targeting ligand
  • cysteine replacement
  • hepatitis E
  • multivalent ligand display
  • virus-like particle

ASJC Scopus subject areas

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Development

Cite this

Chen, C. C., Xing, L., Stark, M., Ou, T., Holla, P., Xiao, K., ... Cheng, R. H. (2016). Chemically activatable viral capsid functionalized for cancer targeting. Nanomedicine, 11(4), 377-390. https://doi.org/10.2217/nnm.15.207

Chemically activatable viral capsid functionalized for cancer targeting. / Chen, Chun Chieh; Xing, Li; Stark, Marie; Ou, Tingwei; Holla, Prasida; Xiao, Kai; Kamita, Shizuo G.; Hammock, Bruce D.; Lam, Kit; Cheng, R. Holland.

In: Nanomedicine, Vol. 11, No. 4, 01.02.2016, p. 377-390.

Research output: Contribution to journalArticle

Chen, CC, Xing, L, Stark, M, Ou, T, Holla, P, Xiao, K, Kamita, SG, Hammock, BD, Lam, K & Cheng, RH 2016, 'Chemically activatable viral capsid functionalized for cancer targeting', Nanomedicine, vol. 11, no. 4, pp. 377-390. https://doi.org/10.2217/nnm.15.207
Chen CC, Xing L, Stark M, Ou T, Holla P, Xiao K et al. Chemically activatable viral capsid functionalized for cancer targeting. Nanomedicine. 2016 Feb 1;11(4):377-390. https://doi.org/10.2217/nnm.15.207
Chen, Chun Chieh ; Xing, Li ; Stark, Marie ; Ou, Tingwei ; Holla, Prasida ; Xiao, Kai ; Kamita, Shizuo G. ; Hammock, Bruce D. ; Lam, Kit ; Cheng, R. Holland. / Chemically activatable viral capsid functionalized for cancer targeting. In: Nanomedicine. 2016 ; Vol. 11, No. 4. pp. 377-390.
@article{3e7d798e4a104ea18b41e6f923300376,
title = "Chemically activatable viral capsid functionalized for cancer targeting",
abstract = "Aim: To design a theranostic capsule using the virus-like nanoparticle of the hepatitis E virus modified to display breast cancer cell targeting functional group (LXY30). Methods: Five surface-exposed residues were mutated to cysteine to allow conjugation to maleimide-linked chemical groups via thiol-selective linkages. Engineered virus-like nanoparticles were then covalently conjugated to a breast cancer recognized ligand, LXY30 and an amine-coupled near-infrared fluorescence dye. Results: LXY30-HEV VLP was checked for its binding and entry to a breast cancer cell line and for tumor targeting in vivo to breast cancer tissue in mice. The engineered virus-like nanoparticle not only targeted cancer cells, but also appeared immune silent to native hepatitis E virus antibodies due to epitope disruption at the antibody-binding site. Conclusion: These results demonstrate the production of a theranostic capsule suitable for cancer diagnostics and therapeutics based on surface modification of a highly stable virus-like nanoparticle.",
keywords = "cycloaddition of targeting ligand, cysteine replacement, hepatitis E, multivalent ligand display, virus-like particle",
author = "Chen, {Chun Chieh} and Li Xing and Marie Stark and Tingwei Ou and Prasida Holla and Kai Xiao and Kamita, {Shizuo G.} and Hammock, {Bruce D.} and Kit Lam and Cheng, {R. Holland}",
year = "2016",
month = "2",
day = "1",
doi = "10.2217/nnm.15.207",
language = "English (US)",
volume = "11",
pages = "377--390",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Chemically activatable viral capsid functionalized for cancer targeting

AU - Chen, Chun Chieh

AU - Xing, Li

AU - Stark, Marie

AU - Ou, Tingwei

AU - Holla, Prasida

AU - Xiao, Kai

AU - Kamita, Shizuo G.

AU - Hammock, Bruce D.

AU - Lam, Kit

AU - Cheng, R. Holland

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Aim: To design a theranostic capsule using the virus-like nanoparticle of the hepatitis E virus modified to display breast cancer cell targeting functional group (LXY30). Methods: Five surface-exposed residues were mutated to cysteine to allow conjugation to maleimide-linked chemical groups via thiol-selective linkages. Engineered virus-like nanoparticles were then covalently conjugated to a breast cancer recognized ligand, LXY30 and an amine-coupled near-infrared fluorescence dye. Results: LXY30-HEV VLP was checked for its binding and entry to a breast cancer cell line and for tumor targeting in vivo to breast cancer tissue in mice. The engineered virus-like nanoparticle not only targeted cancer cells, but also appeared immune silent to native hepatitis E virus antibodies due to epitope disruption at the antibody-binding site. Conclusion: These results demonstrate the production of a theranostic capsule suitable for cancer diagnostics and therapeutics based on surface modification of a highly stable virus-like nanoparticle.

AB - Aim: To design a theranostic capsule using the virus-like nanoparticle of the hepatitis E virus modified to display breast cancer cell targeting functional group (LXY30). Methods: Five surface-exposed residues were mutated to cysteine to allow conjugation to maleimide-linked chemical groups via thiol-selective linkages. Engineered virus-like nanoparticles were then covalently conjugated to a breast cancer recognized ligand, LXY30 and an amine-coupled near-infrared fluorescence dye. Results: LXY30-HEV VLP was checked for its binding and entry to a breast cancer cell line and for tumor targeting in vivo to breast cancer tissue in mice. The engineered virus-like nanoparticle not only targeted cancer cells, but also appeared immune silent to native hepatitis E virus antibodies due to epitope disruption at the antibody-binding site. Conclusion: These results demonstrate the production of a theranostic capsule suitable for cancer diagnostics and therapeutics based on surface modification of a highly stable virus-like nanoparticle.

KW - cycloaddition of targeting ligand

KW - cysteine replacement

KW - hepatitis E

KW - multivalent ligand display

KW - virus-like particle

UR - http://www.scopus.com/inward/record.url?scp=84956927664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956927664&partnerID=8YFLogxK

U2 - 10.2217/nnm.15.207

DO - 10.2217/nnm.15.207

M3 - Article

C2 - 26786134

AN - SCOPUS:84956927664

VL - 11

SP - 377

EP - 390

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 4

ER -